'Ozempic Penis' is the new side-effect that people have been turning their heads at, and users are reporting experiencing ...

Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose ...

A new study reveals that bariatric surgery results in significantly greater weight loss compared to popular GLP-1 drugs.

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Scholar Rock (NASDAQ:SRRK) announced Wednesday that its lead candidate, apitegromab, in combination with Eli Lilly’s ...

Indian pharmaceutical companies are gearing up to launch cost-effective versions of the weight-loss and diabetes drug, semaglutide, post patent expiry in 2026.

In a statement, a spokesperson for Ozempic manufacturer Novo Nordisk only said that the company has “been working closely with policymakers in Pennsylvania” to ensure continued access ...

The global diabetic retinopathy market has shown a consistent growth in recent years and is expected to continue for the coming several years. According to a report from Grand View Research said that ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Research symposia focus on new combinations and medication formulations for both obesity and type 2 diabetes, as well as new ...

US chemical output slows, National Resilience consolidates operations, AstraZeneca partners with a Chinese firm, and more ...